



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED							
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER , 2014							
PART I							
(Rs. in lacs except for share data)							
Sr. No.	Particulars	Quarter Ended			Year Ended		
		30th Sep 2014 (Audited)	30th Jun 2014 (Audited)	30th Sep 2013 (Audited)	30th Sep 2014 (Audited)	30th Sep 2013 (Audited)	31st March 2014 (Audited)
1	Income from Operations						
	(a) Gross Sales / Income from Operations	30,749	27,877	26,627	58,626	50,154	104,435
	Less : Excise Duty & Sales Tax	2,161	1,917	1,847	4,078	3,515	7,441
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	28,588	25,960	24,780	54,547	46,639	96,994
	(b) Other Operating Income	39	10	15	49	21	183
	Total income from operations (net)	28,626	25,970	24,795	54,596	46,660	97,176
2	Expenditure						
	(a) Cost of materials consumed	17,685	16,709	16,453	34,394	29,541	57,082
	(b) Purchase of stock-in-trade	2,727	3,195	2,564	5,921	5,046	8,602
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(480)	(2,052)	(1,881)	(2,532)	(2,458)	569
	(d) Employee benefits expense	917	872	832	1,789	1,572	3,241
	(e) Depreciation and Amortisation Expense	746	741	684	1,487	1,353	2,812
	(f) Other expenses	3,537	3,261	3,307	6,797	6,336	13,046
	Total expenses	25,131	22,725	21,958	47,856	41,391	85,351
3	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	3,496	3,245	2,837	6,741	5,269	11,825
4	Other Income	-	-	-	-	-	-
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	3,496	3,245	2,837	6,741	5,269	11,825
6	Finance costs (interest)	944	982	780	1,926	1,508	3,349
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,552	2,262	2,057	4,814	3,760	8,476
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	2,552	2,262	2,057	4,814	3,760	8,476
10	Tax Expenses	677	539	772	1,216	1,292	2,397
	Provision for Taxation - Current	597	480	615	1,077	1,055	2,300
	- MAT Credit Entitlement	-	(21)	-	(21)	-	-
	- Earlier year	-	-	67	-	67	(253)
	Provision for Deferred Taxation	80	80	90	160	170	350
11	Net profit from ordinary Activities after Tax (9-10)	1,875	1,724	1,284	3,599	2,468	6,080
12	Extraordinary items	-	-	92	-	92	92
13	Net Profit for the Period (11+12)	1,875	1,724	1,376	3,599	2,560	6,171
14	Paid-up Equity Share Capital of Rs. 10/- each.	1,211	1,211	1,211	1,211	1,211	1,211
15	Reserves & Surplus (excluding revaluation reserves)	-	-	-	-	-	23,880
16	Earning per share						
	Diluted E P S (in Rs.) (of Rs. 10 /- each) (not annualised)						
	(a) Basic & Diluted (before extraordinary items)	15.49	14.24	11.36	29.72	21.14	50.21
	(b) Basic & Diluted (after extraordinary items)	15.49	14.24	11.36	29.72	21.14	50.97



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals


Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

PART II

A PARTICULARS OF SHAREHOLDING							
1	Public shareholding						
	-Number of Shares	4,842,136	4,852,768	5,024,311	4,842,136	5,024,311	4,890,428
	-Percentage of Total Shareholding	39.99	40.08	41.49	39.99	41.49	40.39
2	Promoters & Promoter Group shareholding						
a)	Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered						
	- Number of Shares	7,266,414	7,255,782	7,084,239	7,266,414	7,084,239	7,218,122
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	100	100	100	100	100	100
	-Percentage of shares(as a % of the total Share capital of the company)	60.01	59.92	58.51	60.01	58.51	59.61
B INVESTOR COMPLAINTS		Qtr Ended 30th Sept, 2014					
	Pending at the beginning of the quarter	0					
	Received during the quarter	4					
	Disposed of during the quarter	4					
	Remaining unresloved at the end of the quarter	0					

Place: Mumbai
Date: 14th November, 2014

For and on behalf of the Board
For AARTI DRUGS LIMITED


HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2014 (Rs. in lacs)			
Sr. No	Particulars	30th September 2014	31st March, 2014
A	EQUITY AND LIABILITIES		
1	Shareholder' funds		
	(a) Share Capital	1,211	1,211
	(b) Reserves and surplus	26,599	23,880
	Total - Shareholders's funds	27,810	25,091
2	Non-current liabilities		
	(a) Long - term borrowings	6,560	7,664
	(b) Deferred tax liabilities (net)	3,261	3,101
	(c) Other long - term liabilities	1,039	1,151
	(d) Long - term provisions	108	-
	Total - Non - current liabilities	10,968	11,916
3	Current liabilities		
	(a) Short - term borrowings	32,967	26,560
	(b) Trade payables	14,249	15,018
	(c) Other current liabilities	4,066	4,418
	(d) Short - term provisions	2,331	1,971
	Total - current liabilities	53,614	47,967
	TOTAL- EQUITY AND LIABILITIES	92,392	84,974
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets (including CWIP)	40,435	38,084
	(b) Non - current investments	505	462
	(c) Long - term loans and advances	916	704
	Total - Non - current assets	41,856	39,250
2	Current assets		
	(a) Inventories	16,869	12,673
	(b) Trade receivables	28,362	27,652
	(c) Cash and cash equivalents	233	440
	(d) Short - term loans and advances	2,953	2,220
	(e) Other non - current assets	2,119	2,739
	Total - current assets	50,536	45,724
	TOTAL - ASSETS	92,392	84,974

Notes:

- The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting hold on 14th November, 2014
- The Board of Directors have declared Interim Dividend of Rs. 5/- per Equity Shares of Rs. 10/- each amounting to Rs. 6,05,42,750/- and 20th November, 2014 has been fixed as record date for the payment of said Interim Dividend.
- Company is operating as a Single Segment Company engaged in Pharmaceuticals Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.

For and on behalf of the Board
For AARTI DRUGS LIMITED

Place: Mumbai

Date: 14th November, 2014


HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)



In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 30th September 2014 and the year to date results for the period from 1st April 2014 to 30th September 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No: 103264W

CA. TEJAS. J. PARIKH
PARTNER
Membership No. 123215
Mumbai, Dated: November 14, 2014





Auditors' Report on Quarterly Financial Results and Year to Date Results of
AARTI DRUGS LTD Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of AARTI DRUGS LTD

We have audited the quarterly financial results of AARTI DRUGS LTD for the quarter ended 30th September 2014, and the year to date results for the period from 1st April 2014 to 30th September 2014 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 on Interim Financial Reporting issued under the Companies (Accounting Standard Rules), 2006 which continue to apply under section 133 of the Companies Act 2013 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

